Marlissa Miller

The plan is intended to upgrade Vitagrus’ manufacturing process so that it can ultimately handle the global market supply.

THR-149 is being evaluated in a Phase 2 clinical trial as a potential treatment for diabetic macular edema, which is expected to readout topline results by the end of this year.

Belite Bio has completed patient enrollment for a trial evaluating Tinlarebant, which is the first ever treatment for Stargardt Disease.

Clearside Biomedical developing a long-acting therapy for the treatment of retinal diseases, including wet AMD.

A new study titled, “Prevalence of Diabetic Retinopathy in the US in 2021,” finds that almost 10 million people in the United States with diabetes have diabetic retinopathy.